{"i": ["axitinib", "sorafenib .", "eNOS inhibitors", "inhibitors", "Sorafenib", "sorafenib", "VSP inhibitor", "sunitinib", "VSP inhibitors", "levantinib"], "o": ["AEs", "mean increase in DBP", "progression - free and overall survival", "grade 2 lipase", "blood pressure ( BP )", "DBP changes", "change in DBP", "mean BP", "pharmacokinetic variance", "steady state plasma", "AUC", "ambulatory DBP", "DBP increases", "standardized office BP measurements", "plasma sorafenib concentrations ( Cavess", "Cavess", "BP elevation", "cardiac nitrite / nitrate production", "ABP monitoring", "diastolic measurements", "unbound fraction", "Total", "12 - hour ambulatory BP", "grade 3 hemoptysis", "concentrations", "22 BP levels and plasma", "mean diastolic BP ( DBP )", "hypertension", "mean 12 - hour ambulatory BP ( ABP ),", "mean change in BP", "baseline BP", "grade \u2265 2 toxicities", "mean blood pressure changes", "grade 2 AEs", "baseline DBP", "progressive disease", "partial response", "mean BP values", "hypertension and rash", "DBP", "hypophosphatemia", "dose reductions", "concentrations .", "BP", "SBP", "ambulatory BP profiles", "plasma exposures", "Systolic measurements", "plasma concentrations", "blood pressure", "Screening BP", "BP response variance", "blood pressure change", "total plasma", "DBP values", "prothrombin time .", "Unbound", "ambulatory systolic blood pressure ( SBP )", "ambulatory BP .", "plasma concentrations .", "mean BP .", "toxicities", "drug levels", "drug exposure", "safety and tolerability", "12 - hour mean DBP", "BP response and plasma", "systolic blood pressure ( SBP ) and diastolic blood pressure ( DBP )", "diastolic blood pressure ( DBP ).", "DBP elevations", "BP responses", "skin reaction , rash", "grade 2 hypertension", "hand - foot syndrome"]}